Information Provided By: 
Fly News Breaks for May 18, 2018
AMGN
May 18, 2018 | 08:46 EDT
Jefferies analyst Michael Yee says the confirmed list price of $6,900 for Amgen's (AMGN) Aimovig is lower than Street expectations of $7,000-$10,000. The analyst thinks the net price could fall to around $5,000-$6,000 as Allergan's (AGN) Botox is around $6,000. Amgen's pricing strategy sends a good message and fits well into the current reimbursement environment, Yee tells investors in a research note. He keeps a Buy rating on the shares with a $200 price target.
News For AMGN From the Last 2 Days
AMGN
Apr 15, 2024 | 07:22 EDT
TD Cowen lowered the firm's price target on Amgen to $360 from $370 and keeps a Buy rating on the shares. The firm updated its model ahead of Q1 earnings based on their sales/scrip trackers and to better align estimates with Q1 and 2024 sales and operating expenses guidance.
